Kathleen S. Capps - 25 Nov 2025 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Reporting relationship: Executive Director of Accounting, Controller (Principal Accounting Officer)
Issuer ticker: ENTA
Reported as of: 25 Nov 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Nov 2025, 17:24:51 UTC
Prior SEC filing: 08 Sep 2025
Next SEC filing: 03 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Matthew Kowalsky as attorney-in-fact

Key filing fact

Kathleen S. Capps filed Form 4 for ENANTA PHARMACEUTICALS INC (ENTA) on 26 Nov 2025.

Key facts

This page summarizes Kathleen S. Capps's Form 4 filing for ENANTA PHARMACEUTICALS INC (ENTA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 26 Nov 2025, 17:24.

Change

Previous filing in this sequence was filed on 08 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002085127 Primary reporting owner

Capps Kathleen S.

Relationship: Executive Director of Accounting, Controller (Principal Accounting Officer)
Address: C/O ENANTA PHARMACEUTICALS, INC., 4 KINGSBURY AVENUE, WATERTOWN
Signature: /s/ Matthew Kowalsky as attorney-in-fact
Signature date: 26 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ENTA transaction

Common Stock

Award

Transaction value: $0
Shares: +3,163
Change %: +54%
Price: $0.000000
Shares after: 8,992
Date: 25 Nov 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ENTA transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +6,325
Change %
Price: $0.000000
Shares after: 6,325
Date: 25 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,325
Exercise price: $13.66
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents a grant of restricted stock units ("RSUs") under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs will vest and settle with respect to 25% of the award on December 1, 2026 and in substantially equal annual installments over the next three anniversaries thereafter.

Footnote F2

Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 25, 2025).

SEC remarks

Executive Director of Accounting, Controller (Principal Accounting Officer)